BIOTECHNOLOGY

Prescient trials show total eradication of cancer

Finfeed Archived Nov 28, 2019

Shares in Prescient Therapeutics Limited (ASX:PTX) surged 50% on Wednesday after the clinical stage oncology company developing personalised medicine approaches to cancer released promising news.

Archer reaches key development milestone

Finfeed Archived Nov 26, 2019

Archer Materials Limited (ASX:AXE) has progressed its graphene-based biosensor technology development by building a first-phase prototype device to test the printing and performance of graphene inks.

Archer materialises the road to commercialisation

Next Investors Archived Nov 25, 2019

Archer Materials (ASX:AXE) announced the successful and scalable assembly of qubit array components of the 12CQ room-temperature qubit processor.

Regeneus soars 60% as Japanese fund supports capital raising

Finfeed Archived Nov 19, 2019

Streamlining of the group’s internal operations and the pending Progenza licensing deal in Japan, will see Regeneus sufficiently funded to commercialisation in Japan.

Interview: Mike Harsh on the evolution of Imaging and Imagion's role

Finfeed Archived Nov 18, 2019

With over 40 years’ experience in the healthcare diagnostic imaging industry, Imagion Biosystems (ASX:IBX) Board member Mike Harsh is one of the world’s most qualified people to speak about the evolution of diagnostics.

Rat's Rant: What's hot, what's not and... the iPod

Finfeed Archived Oct 24, 2019

Redbubble closed up 22% to finish at $177.5c on $5.4 million stock traded. The reason: they released strategic and financial updates for the first quarter (1Q) ended 30 September 2019.

Ten ‘TechKnows’ to test drive

Finfeed Archived Oct 23, 2019

The TechKnow Invest Roadshow provides retail and institutional investors, as well as brokers, an opportunity to learn more about a range of tech and biotech companies.

Rat's Rant: What's hot, what's not and ... more biotech winners

Finfeed Archived Oct 03, 2019

Immuron’s (ASX:IMC) second clinical-stage asset, IMM-529, targets Clostridium difficile Infections (CDI), and is presently in a clinical trial in CDI patients.

Actinogen’s shares surge 460% after Xanamem success

Finfeed Archived Oct 02, 2019

Actinogen Medical (ASX:ACW) released extremely promising results from the XanaHES (Xanamem in Healthy Elderly Subjects) trial.

Rat's Rant: What's hot, what's not and... the Bali anniversary

Finfeed Archived Oct 02, 2019

Actinogen closed up 466% to finish at 5.1c on $15.8 million stock traded. The company announced results from the XanaHES (Xanamem in Healthy Elderly Subjects) trial. The results demonstrate a significant improvement in cognition in trial participants dosed with Xanamem 20mg daily for 12 weeks, compared to placebo.

Rat's Rant: What's hot, what's not and ... Donkey Kong

Finfeed Archived Sep 24, 2019

Osteopore yesterday closed up 260% (yes that's right) to finish at 72.5c on $4.6 million stock traded. The reason: they listed. Osteopore is one of the hottest, if not the hottest, IPOs in the last few years.

Genetic Technologies surges 40% on back of agreement

Finfeed Archived Sep 23, 2019

Provider of world-leading genetic risk assessment test products Genetic Technologies Limited (ASX:GTG), has signed a 3-year Collaboration Agreement with TGen.

Rat's rant: What's hot, what's not and ... Jimi Hendrix

Finfeed Archived Sep 19, 2019

Some of today’s stocks would love to be as hot as Jimi Hendrix in his prime. That’s certainly what they are aiming for.

Rhythm’s lead biomarker successfully differentiates between cancer and healthy samples

Finfeed Archived Sep 19, 2019

New antibodies for the key lead biomarker used in Rhythm Biosciences' (ASX: RHY) ColoSTAT® test can successfully differentiate between cancer and healthy samples, and the test has now been optimised.

A healthy six pack in a hot sector: Part 2

Finfeed Archived Sep 11, 2019

The S&P/ASX 200 Healthcare Sector blitzed the rest of the market, increasing 12.7% against the ASX 200 which interestingly by the start of September was already back in positive territory, up 4.5%.

Imagion MRI applications as a new source of revenue

Finfeed Archived Sep 09, 2019

Imagion Biosystems (ASX:IBX) advised the market of early-stage evidence that the technology could have applications in improving magnetic resonance imaging (MRIs).

Immuron shares soar more than 20%

Finfeed Archived Sep 04, 2019

Immuron’s (ASX:IMC) share price has surged on the back of extremely promising clinical results.

Leading investment firm invests in new CSIRO health technology

Finfeed Archived Aug 08, 2019

The estimated present value of benefits from the CSIRO’s work is around $3.2 billion per year, so it's no surprise that the CSIRO and the rather astute BioScience Managers would eventually cross paths.

Biotechnology